Recurrent Adult Soft Tissue Sarcoma Completed Phase 2 Trials for Trebananib (DB12056)

IndicationStatusPhase
DBCOND0028931 (Recurrent Adult Soft Tissue Sarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01623869Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by SurgeryTreatment